Trial Profile

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Capecitabine; Carboplatin; Eribulin; Paclitaxel; Vinorelbine
Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer
Focus Adverse reactions
Acronyms REVIVAL study

06 Jun 2021 This trial has been discontinued in Netherlands, as per European Clinical Trials Database record.
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
14 Jan 2019 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com